This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies
Experimental Hematology & Oncology Open Access 23 February 2024
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033.
Dang CV, Le A, Gao P . MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009; 15: 6479–6483.
Sheng H, Tang W . Glycolysis inhibitors for anticancer therapy: a review of recent patents. Recent Pat Anticancer Drug Discov 2016; 11: 297–308.
Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queirós O, Preto A et al. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol 2014; 29: 1511–1524.
Sanchez WY, McGee SL, Connor T, Mottram B, Wilkinson A, Whitehead JP et al. Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib. Br J Cancer 2013; 108: 1624–1633.
Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer 2013; 108: 170–178.
Walters DK, Arendt BK, Jelinek DF . CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle 2013; 12: 3175–3183.
Panchabhai S, Kelemen K, Ahmann G, Sebastian S, Mantei J, Fonseca R . Tumor associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia 2016; 30: 951–954.
Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982–2989.
Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467–472.
Usmani SZ, Crowley J, Hoering A, Mitchell A, Waheed S, Nair B et al. Improvement in long-term outcomes with successive total therapy trials for multiple myeloma: are patients now being cured? Leukemia 2013; 27: 226–232.
Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y et al. Metabolic signature identifies novel targets for drug resistance in multiple myeloma. Cancer Res 2015; 75: 2071–2082.
Wong N, De Melo J, Tang D . PKM2, a central point of regulation in cancer metabolism. Int J Cell Biol 2013; 2013: 242513.
He Y, Wang Y, Liu H, Xu X, He S, Tang J et al. Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Leuk Res 2015; 39: 1428–1436.
Kyle RA, Rajkumar SV . Multiple myeloma. N Engl J Med 2004; 351: 1860–1873.
Warner SL, Carpenter KJ, Bearss DJ . Activators of PKM2 in cancer metabolism. Future Med Chem 2014; 6: 1167–1178.
Doherty JR, Cleveland JL . Targeting lactate metabolism for cancer therapeutics. J Clin Invest 2013; 123: 3685–3692.
Fu Z-G, Wang L, Cui H-Y, Peng J-L, Wang S-J, Geng J-J et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget 2016; 7: 9429–9447.
Zhu D, Wang Z, Zhao J-J, Calimeri T, Meng J, Hideshima T et al. The cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med 2015; 21: 572–580.
Colegio OR, Chu N-Q, Szabo AL, Chu T, Rhebergen AM, Jairam V et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 2014; 513: 559–563.
Acknowledgements
RF is a clinical investigator of the Damon Runyon Cancer Research Fund. This work is supported by grants R01 CA83724, ECOG CA 21115T, Predolin Foundation, Mayo Clinic Cancer Center and the Mayo Foundation.
Author contributions
SP and RF contributed to the conception and design of the study. SP performed research and analyzed the data. IS and SS contributed to data interpretation. SP drafted the article, and all authors read, revised the article critically for important intellectual content and gave final approval of the version to be published.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RF has sponsored research from AMGEN, Celgene, Onyx and Sanofi. He has received consulting fees from Bayer, Novartis, Onyx, Pharmacyclics, Sanofi and serves on the advisory committee of Applied Biosciences. He has received a patent for the prognostication of MM based on genetic categorization of the disease. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Panchabhai, S., Schlam, I., Sebastian, S. et al. PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma. Leukemia 31, 991–994 (2017). https://doi.org/10.1038/leu.2016.389
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2016.389
This article is cited by
-
Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies
Experimental Hematology & Oncology (2024)
-
The Lipid Side of Bone Marrow Adipocytes: How Tumor Cells Adapt and Survive in Bone
Current Osteoporosis Reports (2018)